Precipio (PRPO) investor relations material

Executive summary

• Q2 net sales reached $7.0M, up 24% year-over-year; adjusted EBITDA was $0.4M and cash at quarter-end was $3.1M.

• Integrated pathology services and product development support clinical validation and commercialization of diagnostic products.

• Processed 4,652 cases in Q2, up 26% year-over-year; first-half volume was 9,564, up 42%.

Financial highlights

• Q2 net sales were $7.0M, up 24% year-over-year; first-half net sales were $13.7M, up 30%.

• Q2 gross profit was $3.1M, with a 45% margin, versus $2.4M and 43% in Q2 2025; first-half gross profit was $5.9M at a 43% margin.

• Adjusted EBITDA was $0.4M, versus $(0.2)M in Q1 2026; higher revenue and lower stock-based compensation contributed to the improvement.

• Q2 operating loss was $0.6M and net loss was $0.2M (EPS: -$0.12); first-half net loss was $1.7M (EPS: -$0.93).

• Cash was $3.1M at June 30, 2026, versus $2.7M at year-end 2025 and $1.1M at Q2 2025-end.

Outlook and guidance

• H2 priorities include growing revenue and products, converting the commercial pipeline, and translating growth into adjusted EBITDA and cash generation.

• Management expects product pipeline accounts to move to active status in H2 and contribute significantly to growth; pathology is expected to grow organically.

• Continued investment planned in sales capacity, product innovation, and pipeline conversion.